Mechanisms for SGLT-2 inhibitor CV benefits are different from those proposed to influence GLP-1 RA benefits: intravascular volume contraction, decreased cardiac afterload and preload, and improved systolic and diastolic function
Proof of an adverse health condition such as: Deep Vein Thrombosis (DVT) Gallbladder Cancer Gallbladder Removal (prior to March 2022) Gastroparesis Ileus/Bowel Obstruction (w/surgery) Necrotizing Pancreatitis Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Pancreatic Cancer Pulmonary Aspiration Pulmonary Embolism It is important to note that not all individuals who suffered a side effect after using Mounjaro will qualify for a lawsuit
Interested in GLP-1 meds like Ozempic, Wegovy, and Zepbound but not sure whether your insurance will cover them
[Runs his hand along several feet of supplement-packed shelving.] How the heck would you do that when you're traveling
The thymosin beta-4 fragment literature is less well-characterized on pharmacokinetic parameters than the full protein, and that gap is worth noting in any methods section that cites it
Formulation challenges Eczema skin presents a paradox for topical delivery
